Pancreatic cancer's notorious resistance to treatment may finally face a meaningful challenge. With five-year survival rates below 12%, this malignancy represents one of oncology's most formidable adversaries, largely due to ubiquitous RAS mutations that have historically proven "undruggable."
Daraxonrasib, an oral inhibitor targeting both mutant and wild-type RAS proteins, demonstrated a 35% objective response rate in 26 patients with RAS G12-mutated pancreatic ductal adenocarcinoma receiving second-line therapy at 300mg daily. The median response duration reached 8.2 months, with progression-free survival of 8.5 months and overall survival extending to 13.1 months. Treatment-related adverse events affected 96% of the 168-patient cohort, though only 30% experienced grade 3 or higher toxicities, primarily rash, diarrhea, and gastrointestinal symptoms.
This represents a watershed moment in RAS-targeted therapy, as previous attempts to inhibit these proteins faced significant technical hurdles. The drug's ability to bind both GTP-loaded active RAS and maintain activity across multiple RAS variants addresses longstanding pharmaceutical challenges. However, the 35% response rate, while encouraging for pancreatic cancer, still leaves most patients without benefit. The durability question remains critical—whether 8.2-month responses translate into meaningful survival gains requires longer follow-up and comparison with standard therapies. Additionally, the phase 1-2 design limits definitive efficacy conclusions. Nevertheless, for a cancer where incremental progress has been elusive, daraxonrasib's activity profile suggests RAS inhibition may finally transition from theoretical possibility to clinical reality, potentially reshaping treatment paradigms across RAS-driven malignancies.